177Lu-DOTA-HYNIC-Lys(Nal)-Urea-Glu: synthesis and assessment of the ability to target the prostate specific membrane antigen
| Autor: | Tania Hernández-Jiménez, Nallely Jiménez-Mancilla, Blanca Ocampo-García, Enrique Morales-Avila, Erika Azorín-Vega, Luis A. Medina, Flor de María Ramírez, Guillermina Ferro-Flores, Myrna Luna-Gutiérrez, Martha Pedraza-López, Alondra Escudero-Castellanos, Clara Santos-Cuevas |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Health
Toxicology and Mutagenesis Public Health Environmental and Occupational Health medicine.disease Pollution In vitro 030218 nuclear medicine & medical imaging Analytical Chemistry 03 medical and health sciences chemistry.chemical_compound Prostate cancer 0302 clinical medicine Nuclear Energy and Engineering chemistry In vivo 030220 oncology & carcinogenesis LNCaP Glutamate carboxypeptidase II Urea medicine Cancer research DOTA Radiology Nuclear Medicine and imaging Molecular probe Spectroscopy |
| Zdroj: | Journal of Radioanalytical and Nuclear Chemistry. 318:2059-2066 |
| ISSN: | 1588-2780 0236-5731 |
| Popis: | SPECT/CT images have proved the capability of 99mTc-EDDA/HYNIC-Lys(β-naphthylalanine)-NH-CO-NH-Glu to detect prostate cancer tumors in patients. Considering that theranostics combines the potential of therapeutic and diagnostic radionuclides in the same molecular probe, this research aimed to prepare 177Lu-DOTA-HYNIC-Lys(β-naphthylalanine)-NH-CO-NH-Glu (177Lu-iPSMA) and evaluate the in vitro and in vivo radiotracer ability to target the PSMA protein overexpressed in prostate cancer cells (LNCaP). 177Lu-iPSMA, obtained with radiochemical purities of 99%, showed specific in vitro and in vivo recognition for PSMA in prostate cancer cells and high LNCaP-tumor uptake (11 ± 2% ID/g at 24 h). The results obtained warrant further studies to evaluate the therapeutic efficacy of 177Lu-iPSMA. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |